To explore the underlying mechanisms of mIL‐6R blockade in SIRS treatment, we employed RNA‐seq and found that expression of the pro‐inflammatory chemokine Ccl2 significantly decreased after the mIL‐6R mAb treatment. The gene discussed is CCL2; the disease is systemic inflammatory response syndrome.